Hydroxocobalamin is a long-acting form of vitamin B12. Its clearest value is correcting a genuine B12 shortage — more common with age, plant-based diets, and certain medications — reliably reversing anemia, easing nerve symptoms, and lowering a blood marker tied to heart and brain risk. Benefits for those already well-supplied are far less certain. (Full Review)

Protocol

Standard Repletion

1 mg intramuscularly

Three times weekly for two weeks (loading), then every 2–3 months for maintenance

With Nerve Involvement

1 mg on alternate days

Until no further improvement, then 1 mg every two months

Oral Alternative

~1,000 µg daily

High-dose oral B12, absorbed without intrinsic factor, can match injections even in pernicious anemia

Time to effect

Blood & Anemia

6–8 weeks

Reticulocyte response in 3–5 days; hemoglobin and cell size normalize over 6–8 weeks

Homocysteine

4–12 weeks

Elevated homocysteine falls over roughly 4–12 weeks

Nerve Symptoms

Weeks to months

Recovery depends on how long the deficiency was present

Benefits

High: Correction of B12 deficiency and megaloblastic anemia; reduction of elevated homocysteine; reversal of B12-deficiency neurological symptoms

Medium: Slowing of brain atrophy and cognitive decline in at-risk adults; restoration of energy and reduction of fatigue

Low: Mood and depressive symptom support; cardiovascular risk reduction

Speculative: Methylation-mediated epigenetic and longevity effects; vascular tone modulation via nitric oxide scavenging

Contraindications

Hypersensitivity to hydroxocobalamin, cobalt, or injection preservatives

Key Interactions

Nitrous oxide (laughing gas)

Metformin

Proton pump inhibitors and H2 blockers (omeprazole, esomeprazole, ranitidine, famotidine)

Colchicine and chloramphenicol

High-dose folic acid

Risk & Side Effects

High: Injection-site reactions and pain; chromaturia and interference with laboratory tests

Medium: Hypersensitivity and anaphylactic reactions; hypokalemia during correction of severe anemia

Low: Acneiform eruptions and rosacea flares; hyperuricemia and oxalate nephropathy

Speculative: Associations between high serum B12 and mortality; antibody formation against the transcobalamin–B12 complex

Monitoring

Marker	Target	Why
Serum Vitamin B12 (total)	>400–500 pg/mL	Screens overall B12 status
Holotranscobalamin (active B12)	>35–50 pmol/L	Measures the B12 fraction cells can actually use
Methylmalonic Acid (MMA)	<270 nmol/L (lower is better)	Confirms a true cellular B12 shortage
Homocysteine	<9–10 μmol/L	Tracks methylation status and heart/brain risk
Complete Blood Count with MCV	MCV 80–90 fL	Detects megaloblastic anemia
Serum Potassium	4.0–4.5 mmol/L	Guards against hypokalemia during rapid anemia correction
Serum Folate	>5 ng/mL	Ensures the folate partner is adequate
Intrinsic Factor Antibodies	Negative	Identifies pernicious anemia as the cause

Cadence: Recheck B12 status and homocysteine roughly 8–12 weeks after starting to confirm response, then every 6–12 months during maintenance; monitor potassium during the initial correction of severe anemia only.

Qualitative Assessment

Energy levels and freedom from unexplained fatigue
Cognitive clarity and concentration
Mood stability
Resolution of tingling, numbness, or burning in the hands and feet
Balance and steadiness of gait
Comfort of the tongue and mouth (resolution of soreness or inflammation)
Everyday exercise tolerance

Hydroxocobalamin for Health & Longevity

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment